Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00006294
Status:
COMPLETED
Last Update Posted:
2024-04-26
First Post:
2000-09-25
Brief Title:
Genetics of Hypertension Associated Treatments GenHAT
Sponsor:
Donna Arnett 257-5678
Organization:
University of Kentucky
Study Overview
Official Title:
Pharmacological Association of the Angiotensin-Converting Enzyme InsertionDeletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Anti-hypertensive Treatment
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GenHAT
Brief Summary:
To examine whether the association between selected hypertensive genes and combined fatal coronary heart disease and nonfatal myocardial infarction in high-risk hypertensives is modified by the type of antihypertensive treatment leading to differential risks of coronary heart disease
Detailed Description:
BACKGROUND
The study might shed important light on the variation in patient response to antihypertensive agents and improve the ability to pick the right antihypertensive for specific patients GenHAT is an ancillary study to ALLHAT the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT recruited 42515 hypertensives and randomized them to one of four antihypertensive agents lisinopril chlorthalidone amlodipine and doxazosin follow-up will be completed in March 2002
DESIGN NARRATIVE
GenHAT a prospective study ancillary to ALLHAT will characterize hypertension genetic variants and determine their interaction with antihypertensive treatments in relation to coronary heart disease CHD DNA from frozen clots stored at the ALLHAT Central Laboratory will be used to genotype variants of hypertension genes angiotensinogen -6 angiotensin converting enzyme insertiondeletion angiotensin type- 1 receptor alpha-adducin beta2 adrenergic receptor lipoprotein lipase and 10 new hypertension variants expected to be discovered during the course of the study In addition to the primary aim a number of secondary aims will be undertaken to evaluate gene- treatment interactions in relation to other endpoints including all-cause mortality stroke heart failure left ventricular hypertrophy decreased renal function peripheral arterial disease and blood pressure lowering Because of the ethnic and gender diversity of ALLHAT an assessment will be made of the effects of these variants on outcomes in key subgroups age 65 years women African Americans Type II diabetics and whether the gene-treatment interactions in relation to outcomes are consistent across subgroups
The study might shed important light on the variation in patient response to antihypertensive agents and improve the ability to pick the right antihypertensive for specific patients GenHAT is an ancillary study to ALLHAT the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT recruited 42515 hypertensives and randomized them to one of four antihypertensive agents lisinopril chlorthalidone amlodipine and doxazosin follow-up will be completed in March 2002
DESIGN NARRATIVE
GenHAT a prospective study ancillary to ALLHAT will characterize hypertension genetic variants and determine their interaction with antihypertensive treatments in relation to coronary heart disease CHD DNA from frozen clots stored at the ALLHAT Central Laboratory will be used to genotype variants of hypertension genes angiotensinogen -6 angiotensin converting enzyme insertiondeletion angiotensin type- 1 receptor alpha-adducin beta2 adrenergic receptor lipoprotein lipase and 10 new hypertension variants expected to be discovered during the course of the study In addition to the primary aim a number of secondary aims will be undertaken to evaluate gene- treatment interactions in relation to other endpoints including all-cause mortality stroke heart failure left ventricular hypertrophy decreased renal function peripheral arterial disease and blood pressure lowering Because of the ethnic and gender diversity of ALLHAT an assessment will be made of the effects of these variants on outcomes in key subgroups age 65 years women African Americans Type II diabetics and whether the gene-treatment interactions in relation to outcomes are consistent across subgroups
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01HL063082 | NIH | None | httpsreporternihgovquickSearchR01HL063082 |